Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
Department of Pathology, University of British Columbia, Vancouver, BC, Canada.
Can J Neurol Sci. 2023 Jul;50(4):485-494. doi: 10.1017/cjn.2022.69. Epub 2022 May 30.
Frontotemporal dementia (FTD) is a devastating neurodegenerative condition for which there is currently no effective treatment. Although it is much less common than Alzheimer's disease, the impact of FTD is increased by its relatively early onset and high heritability. Clinical heterogeneity and overlap with other neurodegenerative and psychiatric syndromes complicate diagnosis. However, recent advances in our understanding of the molecular basis of FTD provide a foundation for the development of much-needed biomarkers and targeted therapies. This review provides a summary of the recently revised clinical criteria for FTD, highlights diagnostic challenges, briefly summarizes recent molecular discoveries and then focuses on promising developments in biomarkers and clinical trials.
额颞叶痴呆（FTD）是一种破坏性的神经退行性疾病，目前尚无有效的治疗方法。虽然它比阿尔茨海默病少见得多，但由于其发病相对较早且遗传性较高，因此其影响更大。临床异质性和与其他神经退行性和精神综合征的重叠使诊断变得复杂。然而，我们对 FTD 分子基础的理解的最新进展为开发急需的生物标志物和靶向治疗提供了基础。本综述总结了最近修订的 FTD 临床标准，强调了诊断挑战，简要总结了最近的分子发现，然后重点介绍了生物标志物和临床试验的有希望的进展。
